EX-99.1 2 exhibit991_083021.htm EX-99.1 Document
Exhibit 99.1
Identification of the subsidiary which acquired the security being reported on by the parent holding company.
The reported securities are beneficially owned by Takeda Ventures, Inc., a direct wholly-owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc., which, in turn, is a direct subsidiary of Takeda Pharmaceuticals International AG and Takeda Pharmaceutical Company Limited. Takeda Pharmaceuticals International AG is a direct wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.